Oviedo-based Pragmatech has raised €650k to push the commercial rollout of iAST, its AI-driven antibiotic prescribing software that secured CE marking in July 2025. The money targets go-to-market execution rather than lab work. That distinction matters.
The round was led by First Drop, which put in €300k, with Urriellu Ventures adding €175k. The structure also includes a €180k loan from ENISA and the conversion of €162.5k in convertible notes from a prior round into equity.
Pragmatech was founded in 2021 and positions itself squarely at the intersection of AI, pharmacology, microbiology, and infectious diseases. Its core product, iAST, is described by the company as the first CE-marked AI software built to support clinical decision-making in antibiotic prescription.
According to Pragmatech, clinical use has shown fewer prescribing errors and treatment recommendations with lower resistance risk. Claims like that tend to invite scrutiny. Hospitals will decide.
Javier Fernández, co-CEO of Pragmatech, said the funding strengthens the company’s ability to place iAST in hospitals and in front of clinicians who actually prescribe antibiotics under pressure. He pointed to investor backing as validation that the technology is already influencing clinical practice, not just pitching decks.
With this funding round, we are strengthening our ability to bring iAST to the hospitals and healthcare professionals who need it most.
Javier Fernández, co-CEO of Pragmatech
“The support of investors like First Drop and Urriellu Ventures reinforces confidence in our technology and the positive impact it is having on clinical practice,” said Javier Fernández.
The business runs on a B2B model, selling directly into healthcare systems rather than chasing consumers. The pitch is straightforward: better prescribing decisions lead to better outcomes and lower systemic strain. Antibiotic resistance isn’t abstract. It shows up on balance sheets and wards.
Pablo Valledor, co-CEO and CTO, said the round supports both commercial deployment and continued product refinement. He stressed the need for AI tools that clinicians can trust, not just tolerate.
This funding not only enables us to roll out iAST at a commercial level, but also provides us with the resources necessary to continue refining our products and to ensure that artificial intelligence supports clinical decision-making in a safe and effective manner.
Pablo Valledor, co-CEO and CTO
Safe and effective decision support, he said, remains the bar. Maybe the only bar that counts in hospitals.
According to Beinsure, early-stage HealthTech rounds like this increasingly hinge on regulatory milestones rather than raw innovation. CE marking clears one hurdle. Adoption clears the rest.
